NEW YORK , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended September 30, 2020 and provided a
NEW YORK , Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDA Q : POAI) today announces that its chief executive officer, Carl Schwartz , has been featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution
EAGAN, Minn. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to release the CEO’s letter to the shareholders.
Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients. EAGAN, Minn. , Sept. 22, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, a division of Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”)
EAGAN, Minn. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that management, will present at the LD Micro's "LD 500" Virtual Investor
EAGAN, Minn. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Soluble Biotech division, a provider of soluble and stable
EAGAN, Minn. , Aug. 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that its Skyline Medical division, producer of the FDA-approved and
LOS ANGELES , Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Mark Collins , Ph.D., chief innovation officer
Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine NEW YORK , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
Annual Meeting of Stockholders to be Held on September 3, 2020 NEW YORK , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to